AEON News & Events

Aeon Biopharma announced feedback from the FDA following a biosimilar biological product development Type 2a meeting. During the meeting, held in January, the FDA reviewed the company's proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting the company's planned analytical development approach. The agency acknowledged the scientific challenges associated with characterizing a 900 kDa botulinum neurotoxin complex, provided constructive feedback on the company's proposed development approach and analytical assessment plan, and noted that Aeon's analytical methodologies appeared reasonable to support advancement of the program toward a comprehensive analytical similarity package. The company believes this feedback provides a clear framework for the remaining analytical components of its biosimilar development program and plans to complete the majority of its analytical comparability program in 2026. Aeon is currently planning to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program to support approval of ABP-450 as a biosimilar to Botox across all approved therapeutic indications.

Aeon Biopharma (AEON) announced the appointment of John Bencich as CFO. Most recently, he served as CEO of Achieve Life Sciences (ACHV).

Aeon Biopharma files to sell 51.29M shares of Class A common stock for holders

Aeon confirmed that it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance. The company said it looks forward to commenting on the meeting's substance and outcome following receipt of the official meeting minutes from the FDA. Aeon also held a special meeting at which shareholders voted to approve the completion of the transactions announced in November, including the remaining issuances related to the company's private investment in public equity financing and the related exchange of the company's convertible notes held by Daewoong Pharmaceutical. "We are encouraged by the continued progress we are making early in 2026. The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone, and we now look forward to receiving the official meeting minutes within approximately 30 days, which we expect will help inform next steps for the development of ABP-450, our biosimilar to BOTOX(R)," said Rob Bancroft, president and CEO of AEON. "Additionally, we are thankful to our shareholders for their support of the transactions we announced in November, which strengthen our balance sheet, simplify our capitalization structure and position the company to continue executing on our biosimilar program."